Safety and Effectiveness Evaluation of the ISS System in Treatment of Acute Ischemic Stroke (ImpACT-1)

BrainsGate

Status: Completed

Conditions: Ischemic Stricture of Intestine

Treatments: Device: ISS Active Stimulation

Study type: Interventional

Funder types: Industry

Identifiers

NCT03733236

CLP1000450

Details and patient eligibility

About

The primary objective of this pilot study is the assessment of the safety of the ISS500 System in patients who have experienced an acute ischemic stroke within the anterior circulation.

The secondary objectives of this study are to examine the effectiveness of the ISS500 System implantation in the treatment of acute ischemic stroke.

Full description

The study is an open label study in which a comparative group of patients will be prospectively selected from a resource of clinical trial data, the Virtual International Stroke Trials Archive (VISTA), on the basis of similar eligibility criteria and match for principal prognostic variables available at trial entry. Data from patients will be transferred to VISTA in a real time or at most, weekly basis and comparative group patients will be prospectively matched throughout the recruitment period. The VISTA investigators will be blinded to treatment group when receiving data from BrainsGate. The VISTA investigators will match each recruited BrainsGate patient with 3 patients from the VISTA archive. The matching criteria will include age ± 4 years; baseline NIH score matched exactly, and side of infarct.

In addition, to the end of treatment visit, in which implanted patients will undergo a device removal procedure, two follow-up visits will be performed. The visits should be performed at 30±5, and at 90±5 post enrollment. Aggregate trial duration will be ~100 days per patient, and the overall study duration will be up to 18 months.

Enrollment: 98 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age: ≥ 18 years and ≤ 85 of both genders
2. Patients with symptoms and signs of an acute ischemic hemispheric stroke within the anterior circulation.
3. NIHSS ≥ 7 and ≤ 20
4. Treatment can be initiated within the first 24 hours following stroke onset or since last seen normal.
5. Signed informed consent has been obtained from the patient him/herself or his/her legally authorized representative

Exclusion criteria

1. Time interval since onset of symptoms undetermined

2. Treatment with ISS500 System can't start within the first 24 hours post stroke onset

3. Any other imaging diagnosis including tumor, abscess, primary intracranial hemorrhage (ICH) or secondary hemorrhage (PH1-PH2) (H1 and H2 are allowed); or symptoms suspicious for sub-arachnoid hemorrhage, etc

4. Clinical syndrome of an acute stroke due to lacunar infarct (pure motor hemiparesis, ataxic hemiparesis, sensorimotor stroke), unless brain imaging demonstrates a relevant lesion > 1.5 cm in size

5. Not a stroke in the anterior circulation

6. Minor stroke with non-disabling deficit or rapidly improving neurological symptoms with a high probably to Transient Ischemic Attack (TIA)

7. Eligible to or treated with IV or IA t-PA or mechanical thrombolysis

8. Baseline NIHSS >20 or < 7

9. Neurological deficit that has led to stupor or coma (NIHSS level of consciousness score greater than or equal to 2)

10. History of stroke in previous 6 months

11. Pre-existing disability; Modified Rankin Score > 2 upon screening

12. Patients under oral anticoagulants or having received heparin within 48 hours, and / or with elevated activated partial thromboplastin time (aPTT) (or INR)

13. High clinical suspicion of septic embolus

14. Severe cardiac disease: evidence of congestive heart failure or has history of endstage cardiovascular disease (e.g. CHF NYHA Class III or IV or unstable angina)

15. Uncontrolled hypertension upon enrollment (systolic >185 mmHg and/or diastolic >110 mmHg)

16. Serious systemic infection

17. Women known to be pregnant or having a positive or indeterminate pregnancy test

18. Patients with other implanted neural stimulator

19. Orthodontics or non-Hygienic condition/ problems that prevent procedures within the mouth

20. MRI2 contraindications, such as but not limited to:

    • Central nervous system aneurysm clips
    • Implanted cardiac pacemaker or defibrillator;
    • Cochlear implant
    • Ocular foreign body (e.g. metal shavings)
    • Insulin pump
    • Metal shrapnel or bullet
    • Any implanted device that is incompatible with MRI.
    • Patients with a condition precluding entry into the scanner (e.g. morbid obesity, claustrophobia, etc.)

21. Life expectancy < 1 year from other causes

22. Currently participating in any other clinical trial

23. Patients unable or unwilling to follow protocol requirements

24. Massive stroke, defined as acute parenchymal hypodense lesion or effacement of cerebral sulci in over a 2/3 of the MCA territory per CT (or equivalent per T2/Flair/DWI MRI)

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

98 participants in 1 patient group

Active Stimulation

Experimental group

Description:

The Implant will be implanted using a minimal invasive approach. Following implantation, a CT localization imaging should be performed as soon as possible following the implant procedure. ISS (Ischemic Stroke System) stimulation of the SPG (Sphenopalatine Ganglionduring) for 5 consecutive days.

Treatment:

Device: ISS Active Stimulation